Vibalogics To Invest $150 M in US Virotherapy Mfg Facility

By Miranda Greenberg -

November 12, 2020

Vibalogics, a CDMO of oncolytic viruses, viral vector vaccines, and viral vectors, has initiated Phase I of a $150-million investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.

The three-year investment plan includes the build-out of a 110,000-square-foot facility with an investment totaling $150 million for redevelopment, equipment, and personnel. The facility will include 2000-L scale bioreactors and additional fill–finish capabilities. The company expects the site to be operational by the second half of 2021.

The company now provides process development, manufacturing, testing and fill–finish services for early-phase clinical trials from its 50,000-square-foot facility in Cuxhaven, Germany.

In early September (September 2020), Vibalogics appointed ex-Lonza executive Tom Hochuli as Chief Executive Officer. The company was also recently selected by Johnson & Johnson (J&J) as one of its manufacturing partners for J&J’s investigational COVID-19 vaccine.

In May 2019, Vibalogics was acquired by Ampersand Capital Partners, a private-equity firm.

Source: Vibalogics